Compare Top Solutions in:
FEATURES >> 15 Top Blockbuster Contenders | 10 Promising Therapeutic Vaccines
Britain's state health service has advised against paying for Pfizer's inhaled insulin Exubera, saying that the therapy isn't worth the added cost. Pfizer called the decision "perverse and short-sighted." Article
SHARE
WITH: